CA4 and cancer: Interestingly, (CA-4), a tubulin binding agent best known as a vascular disrupting drug and currently in clinical development for ovarian and anaplastic thyroid cancers (Grisham et al, 2018), is one of only few compounds known to induce RhoA kinase activity in the cancer vasculature (Williams et al, 2014).